tirzepatide adolescent obesity trial FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment Tirzepatide Pills | GoodGirlRx

10.14336/ad.2021.1029 Aging Dis

However, if fatigue is severe or worsens, your provider may slow your dose escalation or investigate other causes

Before matching, patients in the trial eligible and expanded populations initiating semaglutide or tirzepatide were younger, more likely to be white and were more frequently prescribed sulfonylureas compared to sitagliptin or dulaglutide users

Side effects and safety The most common adverse events with both drugs are gastrointestinal: nausea, loose stools or constipation, occasional vomiting, and a queasy fullness after meals

[14] [39] In December 2025, the FDA approved an oral version of semaglutide for weight management, using the same brand name (Wegovy) as the injectable version

This can make you eat fewer calories